Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT03323034 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Primary Central Nervous System Neoplasm

Interventions

DRUG: Irinotecan
DRUG: Pevonedistat
DRUG: Temozolomide

Sponsor

Children's Oncology Group

Collaborators

[object Object]